Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michel Delforge

Showing results (101-110 of 188) with videos related to

Pageof 19
Sort By:
Clinical Hematology International|January 19, 2023
Phase I Study of Safety and Pharmacokinetics of RO7297089, an Anti-BCMA/CD16a Bispecific Antibody, in Patients with Relapsed, Refractory Multiple MyelomaTorben Plesner, Simon J Harrison, Hang Quach, et al.
Cytotherapy|May 14, 2017
Multipotent adult progenitor cells improve the hematopoietic function in myelodysplasiaValerie D Roobrouck, Esther Wolfs, Michel Delforge, et al.
The Lancet. Haematology|February 29, 2024
Health-related quality of life in patients with triple-class exposed relapsed and refractory multiple myeloma treated with idecabtagene vicleucel or standard regimens: patient-reported outcomes from the phase 3, randomised, open-label KarMMa-3 clinical trialMichel Delforge, Krina Patel, Laurie Eliason, et al.
Frontiers in Medicine|July 23, 2021
Patient Preferences for Multiple Myeloma Treatments: A Multinational Qualitative StudyRosanne Janssens, Tamika Lang, Ana Vallejo, et al.
Neurology|November 8, 2014
Sporadic late-onset nemaline myopathy with MGUS: long-term follow-up after melphalan and SCTNicol C Voermans, Olivier Benveniste, Monique C Minnema, et al.
Frontiers in Oncology|September 6, 2024
The novel family of Warbicin<sup>®</sup> compounds inhibits glucose uptake both in yeast and human cells and restrains cancer cell proliferationWard Vanthienen, Juan Fernández-García, Maria Francesca Baietti, et al.
Leukemia & Lymphoma|June 9, 2016
Pomalidomide plus low-dose dexamethasone in patients with relapsed/refractory multiple myeloma and moderate renal impairment: a pooled analysis of three clinical trialsDavid S Siegel, Katja C Weisel, Meletios A Dimopoulos, et al.
Annals of Hematology|June 25, 2020
COVID-19, impact on myeloma patientsInès Dufour, Juliette Raedemaeker, Fabio Andreozzi, et al.
The Oncologist|July 27, 2014
European perspective on multiple myeloma treatment strategies in 2014Heinz Ludwig, Pieter Sonneveld, Faith Davies, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 28, 2009
VMP (Bortezomib, Melphalan, and Prednisone) is active and well tolerated in newly diagnosed patients with multiple myeloma with moderately impaired renal function, and results in reversal of renal impairment: cohort analysis of the phase III VISTA studyMeletios A Dimopoulos, Paul G Richardson, Rudolf Schlag, et al.
Pageof 19

Showing results (101-110 of 188) with videos related to

Sort By:
Pageof 19
Clinical Hematology International|January 19, 2023
Phase I Study of Safety and Pharmacokinetics of RO7297089, an Anti-BCMA/CD16a Bispecific Antibody, in Patients with Relapsed, Refractory Multiple MyelomaTorben Plesner, Simon J Harrison, Hang Quach, et al.
Cytotherapy|May 14, 2017
Multipotent adult progenitor cells improve the hematopoietic function in myelodysplasiaValerie D Roobrouck, Esther Wolfs, Michel Delforge, et al.
The Lancet. Haematology|February 29, 2024
Health-related quality of life in patients with triple-class exposed relapsed and refractory multiple myeloma treated with idecabtagene vicleucel or standard regimens: patient-reported outcomes from the phase 3, randomised, open-label KarMMa-3 clinical trialMichel Delforge, Krina Patel, Laurie Eliason, et al.
Frontiers in Medicine|July 23, 2021
Patient Preferences for Multiple Myeloma Treatments: A Multinational Qualitative StudyRosanne Janssens, Tamika Lang, Ana Vallejo, et al.
Neurology|November 8, 2014
Sporadic late-onset nemaline myopathy with MGUS: long-term follow-up after melphalan and SCTNicol C Voermans, Olivier Benveniste, Monique C Minnema, et al.
Frontiers in Oncology|September 6, 2024
The novel family of Warbicin<sup>®</sup> compounds inhibits glucose uptake both in yeast and human cells and restrains cancer cell proliferationWard Vanthienen, Juan Fernández-García, Maria Francesca Baietti, et al.
Leukemia & Lymphoma|June 9, 2016
Pomalidomide plus low-dose dexamethasone in patients with relapsed/refractory multiple myeloma and moderate renal impairment: a pooled analysis of three clinical trialsDavid S Siegel, Katja C Weisel, Meletios A Dimopoulos, et al.
Annals of Hematology|June 25, 2020
COVID-19, impact on myeloma patientsInès Dufour, Juliette Raedemaeker, Fabio Andreozzi, et al.
The Oncologist|July 27, 2014
European perspective on multiple myeloma treatment strategies in 2014Heinz Ludwig, Pieter Sonneveld, Faith Davies, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 28, 2009
VMP (Bortezomib, Melphalan, and Prednisone) is active and well tolerated in newly diagnosed patients with multiple myeloma with moderately impaired renal function, and results in reversal of renal impairment: cohort analysis of the phase III VISTA studyMeletios A Dimopoulos, Paul G Richardson, Rudolf Schlag, et al.
Pageof 19